CA3001014A1 - Mrna cap analogs and methods of mrna capping - Google Patents
Mrna cap analogs and methods of mrna capping Download PDFInfo
- Publication number
- CA3001014A1 CA3001014A1 CA3001014A CA3001014A CA3001014A1 CA 3001014 A1 CA3001014 A1 CA 3001014A1 CA 3001014 A CA3001014 A CA 3001014A CA 3001014 A CA3001014 A CA 3001014A CA 3001014 A1 CA3001014 A1 CA 3001014A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- halo
- optionally substituted
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242881P | 2015-10-16 | 2015-10-16 | |
| US62/242,881 | 2015-10-16 | ||
| PCT/US2016/057405 WO2017066793A1 (en) | 2015-10-16 | 2016-10-17 | Mrna cap analogs and methods of mrna capping |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3001014A1 true CA3001014A1 (en) | 2017-04-20 |
Family
ID=57219027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3001014A Abandoned CA3001014A1 (en) | 2015-10-16 | 2016-10-17 | Mrna cap analogs and methods of mrna capping |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190225644A1 (enExample) |
| EP (1) | EP3362460A1 (enExample) |
| JP (1) | JP2018530587A (enExample) |
| AU (1) | AU2016340183A1 (enExample) |
| CA (1) | CA3001014A1 (enExample) |
| WO (1) | WO2017066793A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
| WO2018075827A1 (en) | 2016-10-19 | 2018-04-26 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
| CN119351474A (zh) | 2017-02-22 | 2025-01-24 | 克里斯珀医疗股份公司 | 用于基因编辑的组合物和方法 |
| BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
| EP3673069A1 (en) | 2017-08-22 | 2020-07-01 | CureVac AG | Bunyavirales vaccine |
| US11692002B2 (en) | 2017-11-08 | 2023-07-04 | CureVac SE | RNA sequence adaptation |
| EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
| WO2019170731A1 (en) * | 2018-03-07 | 2019-09-12 | Sanofi | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same |
| CA3093509A1 (en) * | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| DE202019006199U1 (de) | 2018-04-17 | 2026-01-12 | CureVac SE | Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung |
| CN108484690B (zh) * | 2018-05-16 | 2021-04-30 | 新乡拓新药业股份有限公司 | 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法 |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| EP3846822A4 (en) * | 2018-09-04 | 2022-07-06 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| US12492425B2 (en) | 2018-12-21 | 2025-12-09 | CureVac SE | Methods for RNA analysis |
| CN113453707A (zh) | 2018-12-21 | 2021-09-28 | 库瑞瓦格股份公司 | 用于疟疾疫苗的rna |
| EP4491229A3 (en) | 2019-02-08 | 2025-05-14 | CureVac SE | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| JP2022544412A (ja) | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 |
| CN112390838A (zh) * | 2019-08-14 | 2021-02-23 | 斯微(上海)生物科技有限公司 | 一种改性核苷及其合成方法 |
| IL322998A (en) * | 2019-09-05 | 2025-10-01 | Mitorainbow Therapeutics Inc | Treatment of mitochondrial DNA depletion disorders |
| CN114901360A (zh) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | 用于递送核酸的新型脂质纳米颗粒 |
| EP3886897A1 (en) | 2020-02-04 | 2021-10-06 | CureVac AG | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN113521269A (zh) | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
| CN116322758A (zh) | 2020-05-29 | 2023-06-23 | 库尔维科欧洲股份公司 | 基于核酸的组合疫苗 |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| EP4208549A4 (en) * | 2020-09-04 | 2025-04-16 | Verve Therapeutics, Inc. | Compositions and methods for capping RNAs |
| US20240299309A1 (en) | 2020-12-22 | 2024-09-12 | CureVac SE | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| MX2023011400A (es) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
| WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
| JP7688152B2 (ja) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ， インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| EP4355756A4 (en) | 2021-06-18 | 2025-08-13 | Hongene Biotech Corp | N-ACETYLGALACTOSAMINE FUNCTIONALIZED NUCLEOSIDES |
| WO2023007019A1 (en) * | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| US20240342206A1 (en) | 2021-07-30 | 2024-10-17 | CureVac SE | mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES |
| JP7719954B2 (ja) | 2021-08-18 | 2025-08-06 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
| JP2024532271A (ja) | 2021-08-30 | 2024-09-05 | ホンジーン バイオテック コーポレイション | 官能化ｎ－アセチルガラクトサミンアナログ |
| CN117940158A (zh) | 2021-09-03 | 2024-04-26 | 库瑞瓦格欧洲公司 | 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒 |
| IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CN118401539A (zh) | 2021-12-15 | 2024-07-26 | 兆维生物科技公司 | 官能化的n-乙酰半乳糖胺类似物 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| US12037616B2 (en) | 2022-03-01 | 2024-07-16 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions |
| TW202403046A (zh) | 2022-03-21 | 2024-01-16 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 用於治療脂蛋白相關的疾病之方法及組成物 |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| WO2023246860A1 (zh) * | 2022-06-22 | 2023-12-28 | 江苏申基生物科技有限公司 | 一种起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115109110B (zh) * | 2022-06-22 | 2024-07-12 | 江苏申基生物科技有限公司 | 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115057903B (zh) * | 2022-06-22 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN114853836B (zh) * | 2022-06-24 | 2024-05-14 | 江苏申基生物科技有限公司 | 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CA3267272A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | FLU VIRUS VACCINES |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| CN116143854A (zh) * | 2022-11-08 | 2023-05-23 | 江苏申基生物科技有限公司 | 一种核糖环修饰的mRNA帽类似物及其制备方法和应用 |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| CN115947759A (zh) * | 2022-12-13 | 2023-04-11 | 安徽大学 | 一种治疗新冠药物瑞德西韦的制备方法 |
| EP4658239A1 (en) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| JP2026509258A (ja) | 2023-03-08 | 2026-03-17 | キュアバック エスイー | 核酸送達のための新規な脂質ナノ粒子製剤 |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4701657A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| CN116554250A (zh) * | 2023-05-04 | 2023-08-08 | 江苏申基生物科技有限公司 | 一种pace结构修饰的帽类似物及其应用 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024235451A1 (en) | 2023-05-16 | 2024-11-21 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2024245907A1 (en) | 2023-05-26 | 2024-12-05 | CureVac SE | Cancer antigens |
| EP4731655A1 (en) | 2023-06-23 | 2026-04-29 | CureVac SE | Nucleic acid encoded antibodies |
| AU2024307985A1 (en) * | 2023-06-26 | 2026-02-05 | Elonova Co., Ltd. | Novel modified trinucleotide capping derivative, and mrna into which capping derivative is introduced |
| US20250027087A1 (en) | 2023-07-21 | 2025-01-23 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| CN116987137B (zh) * | 2023-09-26 | 2024-01-02 | 江苏申基生物科技有限公司 | 一种加帽化合物及其在mRNA加帽中的应用 |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025141025A2 (en) * | 2023-12-26 | 2025-07-03 | Eleven Therapeutics Ltd | Novel capping strategies for mrna 5'cap |
| US20250269059A1 (en) | 2024-02-27 | 2025-08-28 | Crispr Therapeutics Ag | Rt editing compositions and methods |
| WO2025186726A1 (en) | 2024-03-05 | 2025-09-12 | Crispr Therapeutics Ag | Modulating expression of agt (angiotensinogen) gene |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6111095A (en) * | 1995-06-07 | 2000-08-29 | Merck & Co., Inc. | Capped synthetic RNA, analogs, and aptamers |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US5962271A (en) * | 1996-01-03 | 1999-10-05 | Cloutech Laboratories, Inc. | Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end |
| CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| AU744755B2 (en) | 1997-11-12 | 2002-03-07 | Brigham And Women's Hospital | The translation enhancer element of the human amyloid precursor protein gene |
| US6429301B1 (en) * | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| EP1073730A1 (en) * | 1998-04-17 | 2001-02-07 | Whitehead For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
| US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| EP1259602A1 (en) | 2000-01-28 | 2002-11-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
| US8273866B2 (en) * | 2002-02-20 | 2012-09-25 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA) |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| EP1903054A3 (de) * | 2001-06-05 | 2008-07-23 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Gentherapie |
| DE10162480A1 (de) * | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| HUE043492T2 (hu) * | 2005-08-23 | 2019-08-28 | Univ Pennsylvania | Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására |
| CA2620420A1 (en) | 2005-08-24 | 2007-03-01 | The Scripps Research Institute | Translation enhancer-element dependent vector systems |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| WO2008016473A2 (en) * | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸 |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8859229B2 (en) * | 2007-02-02 | 2014-10-14 | Yale University | Transient transfection with RNA |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| CN103911378A (zh) | 2007-12-11 | 2014-07-09 | 斯克利普斯研究所 | 涉及mRNA翻译增强因子的组合物和方法 |
| CN101932707B (zh) | 2008-01-31 | 2013-08-21 | 库瑞瓦格有限责任公司 | 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物 |
| KR101806314B1 (ko) * | 2008-04-03 | 2017-12-07 | 스프링 뱅크 파마슈티칼스, 인크. | 바이러스 감염증을 치료하기 위한 조성물 및 방법 |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| CA2753362C (en) * | 2009-02-24 | 2018-06-19 | The Scripps Research Institute | Reengineering mrna primary structure for enhanced protein production |
| EP2281579A1 (en) * | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| PL3338765T3 (pl) * | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| EP3072961A1 (en) * | 2010-04-16 | 2016-09-28 | Children's Medical Center Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
| US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| US8969545B2 (en) * | 2011-10-18 | 2015-03-03 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| MX357803B (es) | 2012-03-27 | 2018-07-24 | Curevac Ag | Moléculas de ácido nucleico artificiales. |
| SG11201405545XA (en) | 2012-03-27 | 2014-11-27 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
| ES2719598T3 (es) | 2012-05-25 | 2019-07-11 | Curevac Ag | Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables) |
| ES2921623T3 (es) * | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| WO2014127917A1 (en) | 2013-02-22 | 2014-08-28 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| EA201591286A1 (ru) * | 2013-03-14 | 2016-02-29 | Шир Хьюман Дженетик Терапис, Инк. | Количественная оценка эффективности кэп матричной рнк |
| WO2015002667A1 (en) | 2013-07-01 | 2015-01-08 | Myq, Inc. | A location regulated point-of-sale system and enhancements |
| US20150050738A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating rna |
| AU2014310933B2 (en) | 2013-08-21 | 2020-05-14 | CureVac SE | Method for increasing expression of RNA-encoded proteins |
| CN105517569A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
| WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
| JP6678582B2 (ja) | 2013-08-21 | 2020-04-08 | キュアバック アーゲー | 肺癌処置のための組成物およびワクチン、組み合わせ、キット |
| CA2915728A1 (en) | 2013-08-21 | 2015-02-26 | Thomas Kramps | Respiratory syncytial virus (rsv) vaccine |
| CN105517566A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 用于治疗前列腺癌的组合物和疫苗 |
| WO2015051173A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc | Polynucleotide molecules and uses thereof |
| WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| GB201320962D0 (en) * | 2013-11-27 | 2014-01-08 | Globalacorn Ltd | Compositions |
| AU2014375404C1 (en) | 2013-12-30 | 2020-11-19 | CureVac Manufacturing GmbH | Methods for RNA analysis |
| WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| WO2017066781A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
-
2016
- 2016-10-17 JP JP2018519312A patent/JP2018530587A/ja active Pending
- 2016-10-17 EP EP16788887.4A patent/EP3362460A1/en not_active Withdrawn
- 2016-10-17 CA CA3001014A patent/CA3001014A1/en not_active Abandoned
- 2016-10-17 AU AU2016340183A patent/AU2016340183A1/en not_active Abandoned
- 2016-10-17 US US15/768,193 patent/US20190225644A1/en not_active Abandoned
- 2016-10-17 WO PCT/US2016/057405 patent/WO2017066793A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018530587A (ja) | 2018-10-18 |
| WO2017066793A1 (en) | 2017-04-20 |
| US20190225644A1 (en) | 2019-07-25 |
| AU2016340183A1 (en) | 2018-04-19 |
| EP3362460A1 (en) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10570388B2 (en) | Phosphate replacement MRNA cap analogs | |
| US11866754B2 (en) | Trinucleotide mRNA cap analogs | |
| US20190225644A1 (en) | Mrna cap analogs and methods of mrna capping | |
| WO2017066789A1 (en) | Mrna cap analogs with modified sugar | |
| WO2017066791A1 (en) | Sugar substituted mrna cap analogs | |
| WO2017066782A1 (en) | Hydrophobic mrna cap analogs | |
| AU2023200127A1 (en) | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | |
| JP2025061366A (ja) | 安定化尾部領域を含むポリヌクレオチド | |
| EP2918275B1 (en) | Alternative nucleic acid molecules and uses thereof | |
| WO2015196118A1 (en) | Alternative nucleic acid molecules and uses thereof | |
| EP3157572A2 (en) | Alternative nucleic acid molecules and uses thereof | |
| EP2931319A1 (en) | Modified nucleic acid molecules and uses thereof | |
| WO2015196128A2 (en) | Alternative nucleic acid molecules and uses thereof | |
| US20220298516A1 (en) | Compositions and methods for delivery of nucleic acids | |
| WO2019036638A1 (en) | METHODS FOR PREPARING MODIFIED RNA | |
| HK40091261A (zh) | 用於5’-加帽的rna合成的寡核苷酸 | |
| HK40032374A (en) | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | |
| HK40032374B (en) | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | |
| NZ623476B2 (en) | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230110 |